戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 re increased following prior euglycemia with alprazolam.
2 ine, atenolol, sulfamethazine, diazepam, and alprazolam.
3  after treatment with either placebo or 1 mg alprazolam.
4 ls associated with the anxiolytic effects of alprazolam.
5  may be related to the anxiolytic effects of alprazolam.
6  both before and during their treatment with alprazolam.
7 were augmented with D-cycloserine (50 mg) or alprazolam (0.25 mg) in a double-blind, placebo-controll
8 pe mice after saline, diazepam (1mg/kg), and alprazolam (0.3mg/kg) injections.
9 1), 450 mg/d (n = 90), or 600 mg/d (n = 89); alprazolam, 1.5 mg/d (n = 93); or placebo (n = 91).
10 ), and 600 mg (-11.8 +/- 0.8, P = .002), and alprazolam (-10.9 +/- 0.8, P = .02).
11  ArcCreER(T2) x eYFP mice were injected with Alprazolam 30 min prior to a 3-shock contextual fear con
12  tested the effects of a single oral dose of alprazolam (a classical benzodiazepine acting as alloste
13                      In contrast to placebo, alprazolam abolished the activation of the rACC after ch
14                                              Alprazolam activation of GABA(A) pathways during day 1 h
15 during CNB (relaxation group), and 0.5-mg of alprazolam administered orally 15 minutes before CNB (me
16                                After 14 d of alprazolam administration (90 mg x kg(-1) x d(-1)), spon
17                       Both acute and chronic alprazolam administration was found to decrease CRF conc
18   We investigated whether the benzodiazepine alprazolam affects activity in distinct brain regions wi
19 razolam increased punished responding, while alprazolam alone had no effect on either non-punished re
20                                              Alprazolam and diazepam increased the amplitude of the n
21 ric acid), and the classical benzodiazepines alprazolam and diazepam.
22                                              Alprazolam and placebo differed significantly on the Cli
23 hters of alcoholics) after challenge does of alprazolam and placebo in comparison with responses in w
24 enobiotics such as methamphetamine, codeine, alprazolam, and morphine, revealing that NIMS can be use
25 , the median environmental emission rates of alprazolam (APZ) and carbamazepine (CBZ) through domesti
26 y suggest that the mood-enhancing effects of alprazolam are greater in daughters of alcoholics than i
27                                              Alprazolam blocked or reversed each of these effects.
28 BAergic circuitry using benzodiazepines like alprazolam can be useful for studying this facial affect
29 GABA(A) receptor subunit expression and that alprazolam can block or reverse those effects.
30 d (GABA) A receptors with the benzodiazepine alprazolam can blunt physiologic responses during next-d
31 hese results demonstrate that punishment and alprazolam can produce reciprocal changes in the mRNA le
32 ude that activation of GABA A receptors with alprazolam can result in widespread neuroendocrine, auto
33  alcoholics and 11 comparison subjects after alprazolam challenge.
34 on vs time (P<.001) and a 2-fold increase in alprazolam clearance (P<.001) were observed following St
35 ed 55 years or older who had used lorazepam, alprazolam, clonazepam, temazepam, and/or zolpidem for c
36 ity exposure augmented with D-cycloserine or alprazolam, compared with placebo, in reducing posttraum
37                         Furthermore, chronic alprazolam decreased basal activity of the hypothalamic-
38          Participants were also administered alprazolam (double-blinded, placebo-controlled crossover
39 y 2 exercise studies, GABA A activation with alprazolam during day 1 euglycemia resulted in significa
40 uring day 2 studies, GABA(A) activation with alprazolam during day 1 euglycemia resulted in significa
41 nobutyric acid (GABA) agonist benzodiazepine alprazolam during fMRI.
42                      GABA(A) activation with alprazolam during prior hypoglycemia caused further sign
43                                              Alprazolam elimination half-life was shortened from a me
44  or hypoglycemic clamps with or without 1 mg alprazolam given 30 min before a clamp.
45 l/L hypoglycemic clamps with or without 1 mg alprazolam given 30 min before each clamp.
46 d end point, the 3 pregabalin groups and the alprazolam group had significantly (P<.01) improved HAM-
47 TSD diagnosis at 3 months posttreatment; the alprazolam group showed a higher rate of PTSD (82.8%) th
48 nly from the placebo group but also from the alprazolam group.
49 n (week 1, P = .06; week 4, P = .32) and the alprazolam groups (week 1, P = .21; week 4, P = .15).
50                                              Alprazolam had no effect on non-suppressed licking, [(3)
51  to 1.42 (95% CI = 1.00-2.02, p = 0.049) for alprazolam + hydrocodone with tizanidine.
52                       In secondary analyses, alprazolam impaired recovery and D-cycloserine enhanced
53 -GSK), 400 mg GSK561679 (high-GSK), and 1 mg alprazolam in a crossover design.
54 s withdrawal from the triazolobenzodiazepine alprazolam in dependent rats and to characterize the tim
55 ll tasks, with and without administration of alprazolam, in a sample of first-degree relatives and he
56      All of these effects were reversed when alprazolam increased punished responding, while alprazol
57                                 We find that alprazolam increases persistence energy in relatives but
58                                              Alprazolam-induced E/I changes are spatially consistent
59                   These results suggest that alprazolam induces sex-specific ensemble activation thro
60 tionally, we address the question of whether alprazolam induces state-dependent memory by altering th
61 without continuous access to mother and with alprazolam injection pretreatments (SI + Alz; three stre
62 ne which brain regions undergo changes after alprazolam injection.
63 rison subjects despite having similar plasma alprazolam levels.
64 ne neurotransmitter systems, indicating that alprazolam may exert its effects by altering neuromodula
65 e also seen in vehicle-treated cage-mates of Alprazolam/Modafinil-treated mice, suggesting that behav
66 ration of the triazolobenzodiazepine agonist alprazolam on CRF peptide concentrations, receptor-bindi
67  GABA(A) activation using the benzodiazepine alprazolam on the neuroendocrine and autonomic nervous s
68 rmone responses were similarly reduced after alprazolam or day 1 hypoglycemia compared with euglycemi
69 c hypoglycemia (2.9 mmol/l) with either 1 mg alprazolam or placebo administered 30 min before the sta
70 ortisol and startle reactivity more than did alprazolam or placebo, findings that are consistent with
71 period taking either diazepam, lorazepam, or alprazolam, patients were treated for 4 weeks with imipr
72 ctivity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics.
73 old decrease in the area under the curve for alprazolam plasma concentration vs time (P<.001) and a 2
74 ere unaffected by punishment were altered by alprazolam plus punishment.
75                               Pregabalin and alprazolam produced a significantly greater reduction in
76 ACC correlated with the anxiolytic effect of alprazolam (r(p) = .52; p = .04).
77 ory gamma-aminobutyric acidergic action with alprazolam reduced anxiety and restored feedback modulat
78 hat chronic administration of the anxiolytic alprazolam reduced indices of CRF and CRF1 receptor func
79           Consistent with previous findings, alprazolam reduced startle potentiation during unpredict
80                      Prior hypoglycemia with alprazolam resulted in further reduction of glucagon and
81 , enhancement of gamma2-GABAAR function with alprazolam reversed the stress-induced increase in the f
82 (relative risk or RR = 1.69); loratadine and alprazolam (RR = 1.86); loratadine and duloxetine (RR =
83 easant mood responses after a single dose of alprazolam than did the comparison subjects despite havi
84 -control ORs of 1.39 (95% CI, 1.17-1.66) for alprazolam to 2.52 (95% CI, 1.89-3.36) for fludiazepam.
85 gs to manage sleep/wake cycles in R6/2 mice, Alprazolam (to put them to sleep) and Modafinil (to wake
86 drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish baseline CYP 3A4 and CYP 2D6 ac
87 ory retention after conventional CFC and, 2) alprazolam treated female and male mice show a decrease
88  a saline injection prior to re-exposure, 3) alprazolam treated female mice exhibit increased EYFP +
89 hanced engram activation in the dCA3, and 4) alprazolam treated females showed less c-Fos + activatio
90                             We found that 1) alprazolam treated male and female mice exhibit a decrea
91 ocortin I-CRF2A function, altered by chronic alprazolam treatment as previously described, returned t
92 te cortex (rACC), which was attenuated after alprazolam treatment.
93 e the full allosteric modulators (FAM), like alprazolam, triazolam, and diazepam, PAMs are virtually
94 izes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines.
95 al variation in differential control energy (alprazolam versus placebo) and (ii) both serotonin and d
96                                              Alprazolam was used to test whether anxiolytic medicatio
97 or associated with the anxiolytic effects of alprazolam were measured in 20 brain regions using in si
98 at GABA A activation with the benzodiazepine alprazolam would blunt counterregulatory responses durin
99 cheduled drugs such as diazepam (Valium) and alprazolam (Xanax).